AIVIS, a leading provider of AI-powered digital pathology solutions, has announced a strategic partnership with NAVER Cloud to accelerate the deployment and adoption of its flagship software platform, Qanti® IHC, across Korea’s healthcare ecosystem.

Through this collaboration, AIVIS’s AI pathology analysis solution, Qanti® IHC, will be available on the NAVER Cloud Platform Marketplace—enabling hospitals, research institutes, and pharmaceutical companies to access its AI-powered analysis capabilities within NAVER Cloud’s secure, high-performance infrastructure.

Qanti® IHC, AIVIS’s core offering, is a medical software solution that uses AI to analyze digitally scanned immunohistochemistry (IHC) tissue images with high precision. It delivers objective, cell-level quantification of key biomarkers—reducing interpretive variability and enhancing reproducibility in both clinical and research settings. AIVIS’s complementary solution, Qanti Micro, improves accessibility by enabling rapid analysis of Ki-67 from microscope-captured images, eliminating the need for costly whole-slide scanners.

As part of the agreement, AIVIS will provide comprehensive support to NAVER Cloud users, including technical documentation, installation guidance, real-time troubleshooting, and regular software updates.

“Partnering with NAVER Cloud represents a major step forward in our cloud-based expansion strategy,” said Daehong Lee, CEO of AIVIS. “It combines our next-generation AI capabilities with a trusted digital infrastructure to make advanced pathology tools more accessible and secure for clinical teams across Korea.”

NAVER Cloud, which holds top certifications in data privacy and information security, offers an ideal platform for organizations managing sensitive medical data. The partnership also positions AIVIS to scale its SaaS (Software as a Service) model more broadly across the medical and research sectors.

A NAVER Cloud spokesperson added,

“We are pleased to support AIVIS in delivering innovative AI technology to more users. This collaboration aligns with our broader commitment to strengthening Korea’s medical AI ecosystem through partnerships with high-potential technology innovators.”

About AIVIS

AIVIS is a South Korea-based medical AI company driving innovation in digital pathology. Its flagship solution, Qanti IHC, provides automated quantification of key biomarkers—including ER, PR, HER2, and Ki-67—with exceptional capability in detecting HER2-low and ultralow cases. Backed by MFDS approval and a growing global presence, AIVIS is dedicated to advancing diagnostic accuracy and enabling AI-powered precision medicine worldwide.